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Oxidative stressCommercial canned ﬁsh species typical in the Italian market were evaluated for their lipid proﬁle. Blueﬁn
tuna samples showed the highest content in omega-3 fatty acids (n-3 PUFA) among the canned ﬁsh sam-
ples analyzed. Tests on H9C2 cardiomyocytes revealed that blueﬁn tuna n-3 PUFA may responsible for a
signiﬁcant cell protection against both physiological and doxorubicin-induced oxidative stress. Analo-
gous tests performed by incubating cardiac cells with n-3 PUFA ethyl esters, of which most of ﬁsh oil
pharmaceutical formulations (FOPF) are based, showed cytotoxicity at high doses. Our results highlighted
that n-3 PUFA contents in a 50 g canned blueﬁn tuna portion would be almost equivalent to and poten-
tially safer than those of 1 FOPF capsule (1000 mg)/die usually suggested for hyperlipidaemic subjects.
Thus, Italian commercial canned blueﬁn tuna could be indicated as a functional food with potential
health beneﬁts for the prevention and care of cardiovascular disorders.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
The European Commission Concerted Action on Functional Food
Science in Europe (FUFOSE) establishes that food is ‘‘functional’’
whether its positive effects on one or more organism functions
are clearly proved so to be determinant for optimizing health con-
ditions and/or decreasing disease incidence, independently from
its nutritional capacity. Moreover, functional food should exert
its potential bioactivities through quantities usually planned in a
conventional dietary regimen (Diplock et al., 1999). Functional
foods can be divided into ‘‘conventional’’ and ‘‘modiﬁed’’. The ﬁrst
category consists in foods whose bioactive components are original
constituents. The second category includes foods whose biological
potential has been technologically inﬂuenced through: addition
of bioactive compounds; removal of antinutrients or toxic
substances; replacement of original components with exogenousbioactive ones; improvement of the bioavailability of original
bioactive constituents.
The correlation between ﬁsh consumption and reduction of car-
diovascular disease risk has focused scientiﬁc research attention
since the seventies of the last century. The protective effects can
be appreciated even when consumption levels are not elevated: a
dietary regimen including at least 30 g ﬁsh/day can promote a sig-
niﬁcant prevention against cardiovascular disorders; particularly,
an increase of 20 g/day in ﬁsh consumption would lead to a
decrease by 7% of death risk for cardiovascular disease in subjects
who occasionally consume ﬁsh (Mozaffarian et al., 2003). Although
the biochemical mechanism of these beneﬁcial properties have not
been clearly explained so far, the positive effects of ﬁsh consump-
tion would be mainly correlated to ﬁsh content in omega 3 long
chain polyunsaturated fatty acids (n-3 PUFA), particularly, docosa-
hexaenoic acid (DHA) and eicosapentaenoic acid (EPA), of which
ﬁsh represents the main dietary source for man (Arino et al.,
2005). The levels of these two fatty acids are strongly variable, both
among the different ﬁsh species and within the same species, due
to the type of diet and breeding. DHA and EPA are not directly pro-
duced by ﬁsh organism; they derive from unicellular algae occur-
ring in the food chain (Arterburn et al., 2006). Assumption levels
of DHA and EPA negatively correlate with the incidence of
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and immune disorders. It has been reported that n-3 PUFA intake
can reduce triglyceride plasma levels and platelet aggregation,
and stabilizes the cardiac rhythm (Harris, 2009). Typical Western
diet provides relatively small amounts of n-3 PUFA, probably inad-
equate to protect the body from chronic degenerative diseases.
This deﬁcit has been indicated as one of the main causes of the
growing incidence of chronic diseases in our society. According
to the American Heart Association Nutrition Committee, two
servings of ﬁsh per week should be consumed for the prevention
of cardiovascular diseases (Kris-Etherton et al., 2002). Previous
studies have revealed that EPA and DHA would exert their best
activity through a synergistic action and that a EPA/DHA ratio of
0.9:1.5 would be adequate for ideal cardiovascular protection
(Mori and Woodman, 2006). In fact, this is precisely the respected
ratio in most of pharmaceutical formulations based on ﬁsh oil n-3
PUFA extracts and indicated for the control of serum triglycerides
in hyperlipidaemic subjects or for the secondary prevention in
patients with previous myocardial infarction.
In the Western world, it is frequently overlooked that ﬁsh often
means canned ﬁsh. Tuna, mackerel, sardines, salmon, and so on,
reach our tables mainly as canned products, keeping intact most
of their nutritional characteristics in quality controlled and long
shelf-life packaging, which greatly facilitate, even in areas not close
to the sea, the possibility of ideal ﬁsh consumption levels. Never-
theless, the biological potential of canned products can be signiﬁ-
cantly different respect to raw ﬁsh mainly due to thermal
processing (ﬁsh steam-cooking and, then, can sterilization). Partic-
ularly, the deleterious effects of high temperatures on canned ﬁsh
n-3 PUFA, mainly DHA and EPA, have been previously reported
(Stephen et al., 2010; Miklavcˇicˇ et al., 2011). Thus, the aim of the
present work was to analyze the lipid proﬁle of the most common
canned ﬁsh species brands in the Italian market in order to evalu-
ate their potential health beneﬁts. The attention was focused on
the products canned in brine considered as the closest to raw ﬁsh,
particularly as regards their lipid proﬁle, if compared to the ones
canned in edible oils.
2. Materials and methods
2.1. Reagents and standards
All chemicals and reagents used were either analytical-reagent or GC grade. All
organic solvents were purchased from Carlo Erba, Milano (Italy). Water was puriﬁed
by a Milli-Qplus system from Millipore (Milford, MA) before use. The standard mix-
ture of fatty acid methyl esters, the pure standards cis-4,7,10,13,16,19-Docosahex-
aenoic acid (DHA, P98%) and cis-5,8,11,14,17-Eicosapentaenoic acid (EPA, P99%),
were purchased from Sigma Chemicals (Milan, Italy).
2.2. Sample collection and lipid extract preparation
Fifty-one cans different ﬁsh species of various common Italian brands were
obtained from retail trades. For each ﬁsh species, different numbers of brands were
chosen as follows: seven, for Thunnus thynnus (blueﬁn tuna); six, for Thunnus albac-
ares (yellowﬁn tuna); eight, for Thunnus alalunga (albacore); seven, for Scomber
scombrus (Atlantic mackerel); ﬁve, for Engraulis encrasicolus (anchovy); six, for Sar-
dina pilchardus (sardine); ﬁve, for Xiphias gladius (swordﬁsh); seven, for Salmo salar
(salmon). For each brand, six lots were taken into consideration. All of the samples
had been canned in brine.
Aliquots (5 g) of each sample were freeze-dried and stored at 20 C until anal-
ysis. Around 0.5 g of powder samples were subjected to lipid extraction according
to AOAC method 948.16, by using a 6-place units Extraction Unit E-816 Soxhlet
(Buchi, Flawil, Switzerland). After centrifugation at 3000g for 5 min, supernatants
were transferred into a pre-weighed scintillation vial, and dried under nitrogen.
2.3. Analysis of fatty acid composition
Lipid extracts (0.1 g) were dissolved in 2 mL of n-eptane and treated with
0.2 mL of 2 N potassium hydroxide methanolic solution (11,2 g of potassium
hydroxide in 100 mL methanol). The mixture was shaked energically for 1 min at
room temperature and then centrifuged (3000g for 5 min). Supernatants werecollected and analysis of fatty acid methyl esters was performed by gas chromatog-
raphy using a DANI GC instrument (DANI Instruments, Milan, Italy) coupled to a
ﬂame ionization detector (FID) and equipped with a HP-5 capillary column (Agilent,
Milan, Italy). The temperature programme started at 150 C (10 min), increased by
2 C/min to 180 C and then increased again by 3 C/min to 240 C (20 min).
2.4. In vitro tests
2.4.1. Preparation of samples for in vitro tests
A mixture of commercial DHA and EPA standards was prepared simulating the
same relative proportions as in canned blueﬁn tuna lipid proﬁle, and has been
referred to as SBTDEM (Simulated Blueﬁn Tuna DHA and EPA Mixture).
A typical commercial ﬁsh oil based pharmaceutical formulation (FOPF) indi-
cated for the control of plasmatic lipid levels was chosen for the in vitro tests. It
consisted in 1000 mg capsules containing PUFA ethyl esters with 85% minimum
levels of EPA and DHA (ratio 0.9–1.5) and the following excipients: D,L a-tocoph-
erol, gelatin succinate, glycerol, ethyl p-oxybenzoate, propyl p-oxybenzoate. Lipid
extraction was performed as described in Section 2.2.
2.4.2. Cell culture and viability test
Rat cardiac H9C2 cells (ATCC, Manassas, VA) were cultured (17–21 passages) in
DMEM supplemented with 10% fetal bovine serum, 100 U/mL of penicillin, and
100 lg/mL of streptomycin in 150 cm2 tissue culture ﬂasks at 37 C in a humidiﬁed
atmosphere of 5% CO2. The cells were fed every 2–3 days, and subcultured once they
reached 70–80% conﬂuence. Cell viability and proliferation were assessed by incu-
bating the culture with SBTDEM and FOPF lipid extract samples (0.01–2 lg), and
doxorubicin 1 lM for 72 h. Lipid extract samples were solubilized by adding
150 lL of DMSO and by mixing it in an orbital shaker for 5 min. As a control,
0.5% DMSO was added to untreated cells.
2.4.3. Preparation of cell extract
Cardiac H9C2 cells were collected by centrifugation and then resuspended in
ice-cold 50 mM potassium phosphate buffer (pH 7.4), containing 2 mM EDTA. The
cells were sonicated, followed by centrifugation at 13,000g for 10 min at 4 C. The
resulting supernatants were collected and kept on ice for immediate measure-
ments, as described below.
2.4.4. Measurement of intracellular ROS accumulation
20 ,70-Dichlorodihydroﬂuorescein diacetate (DCF-DA, 5 lM) was used to detect
intracellular ROS levels in H9C2 cells (Vanden Hoek et al., 1997). DCF-DA is cell
membrane permeable. Once inside the cells, DCF-DA is hydrolyzed by cellular ester-
ases to form DCF, which is trapped intracellularly due to its membrane imperme-
ability. DCF then reacts with intracellular ROS to form the ﬂuorescent product,
20 ,70-dichloroﬂuroscein. Then, the cells were washed once with phosphate buffered
saline (PBS) and lysed in 3 mL ice-cold 10 mM Tris–HCl buffer (pH 7.4) containing
0.2% sodium dodecyl sulfate. The cell lysates were collected and centrifuged at
2000g for 5 min at 4 C. The ﬂuorescence of the supernatants was measured using
a Perkin–Elmer luminescence spectrometer (LS50B) at an excitation wavelength of
495 nm and an emission wavelength of 525 nm.
2.4.5. Measurement of cellular superoxide dismutase activity
Total cellular superoxide dismutase (SOD) activity was measured as follows
(Kirshenbaum and Singal, 1992). Brieﬂy, a reaction mixture contained 50 mM
potassium phosphate buffer (pH 7.8), 1.33 mM diethylenetriaminepentaacetic acid,
1.0 U/mL catalase, 70 lM nitroblue tetrazolium, 0.2 mM xanthine, 50 lM bathocu-
proinedisulfonic acid, and 0.13 mg/mL bovine serum albumin (BSA). A 0.8 mL ali-
quot of the reaction mixture was added to each cuvette, followed by addition of
100 lL of lysate. The cuvettes were pre-warmed at 37 C for 3 min. The formation
of formazan blue was monitored at 560 nm, 37 C for 5 min. The sample total
SOD activity was calculated using a concurrently run SOD (Sigma) standard curve,
and expressed as units per mg of cellular protein. Cellular protein content was
quantiﬁed with Bio-Rad protein assay dye (Hercules, CA) based on the method
which makes use of BSA as the standard.2.4.6. Measurement of caspase-3 activity
Caspase-3 activity was measured using the BD ApoAlert Caspase-3 Fluorogenic
Assay (BD Biosciences Clontech, Palo Alto, CA). Brieﬂy, protein lysates were col-
lected from cells that had been incubated with lioRGJ (0.01–1 lg) for 8 h, as per pro-
tocol. Activity was measured using a ﬂuorescent microplate reader (PerSeptive
Biosystems, Farmington, MA).
2.5. Statistics
Unless otherwise stated, all of the experimental results were expressed as
mean ± standard deviation (SD) of at least ﬁve replications. Statistical analysis of
data was performed by the Student’s t test or two-way ANOVA followed by
Table 1
Lipid proﬁle of different Italian commercial canned ﬁsh species.*
Species FAO name Total lipid SAFA MUFA PUFA n-3 PUFA EPA DHA n-6 PUFA
Thunnus thynnus Blueﬁn tuna 5.64 ± 0.44a 1.55 ± 0.24a,b 1.51 ± 0.37a,e 2.57 ± 0.10a 2.32 ± 0.17a 0.79 ± 0.10a 1.52 ± 0.25a 0.25 ± 0.04a
Thunnus albacares Yellowﬁn tuna 3.74 ± 0.52b 1.41 ± 0.12a,b 0.70 ± 0.11b 1.61 ± 0.32b 1.49 ± 0.39b,d 0.14 ± 0.03b,e 1.28 ± 0.22a,b,e 0.11 ± 0.02b
Thunnus alalunga Albacore 4.70 ± 0.31c,e 1.75 ± 0.22a,b 1.51 ± 0.29a,e 1.43 ± 0.28b 1.28 ± 0.22b,d 0.22 ± 0.04b,c 1.04 ± 0.13b,c,e 0.14 ± 0.03b
Scomber scombrus Atlantic
mackerel
5.73 ± 0.47a 1.92 ± 0.41a,b,c 2.31 ± 0.40c,f 1.48 ± 0.19b 1.10 ± 0.13b,c 0.24 ± 0.04c 0.85 ± 0.10c,d 0.37 ± 0.07c
Engraulis
encrasicolus
Anchovy 4.04 ± 0.20b,d 1.28 ± 0.34b 1.18 ± 0.14a,b,c 1.54 ± 0.16b 1.46 ± 0.31b,d 0.54 ± 0.08d 0.91 ± 0.10c,d,e 0.074 ± 0.006b
Sardina pilchardus Sardine 4.63 ± 0.19d,e 1.64 ± 0.18a,b 1.27 ± 0.33a,b 1.71 ± 0.13b 1.44 ± 0.11b,d 0.51 ± 0.07d 0.92 ± 0.10c,d,e 0.26 ± 0.04a
Xiphias gladius Swordﬁsh 4.58 ± 0.36e 1.60 ± 0.13a,b 2.97 ± 0.26d 0.85 ± 0.21c 0.77 ± 0.25c 0.11 ± 0.02e 0.65 ± 0.14d 0.071 ± 0.004b
Salmo salar Salmon 6.46 ± 0.71f 1.96 ± 0.23c 2.08 ± 0.73e,f 2.41 ± 0.39a 1.58 ± 0.26d 0.38 ± 0.06f 1.19 ± 0.22e 0.82 ± 0.11d
a,b,c,d,e,fMean values in columns with different superscript letters are signiﬁcantly different by the Tukey–Kramer multiple comparison test (P < 0.05).
SAFA: total saturated fatty acids; MUFA: total monounsaturated fatty acids; PUFA: total polyunsaturated fatty acids; EPA: eicosapentaenoic acid (20:5n-3); DHA: docosa-
hexaenoic acid (22:6n-3).
* Data are expressed as mean value (g/100 g fresh weight) ± SD (n = 5).
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between a pair of means. The level of signiﬁcance (a-value) was 95% in all cases
(P < 0.05).Table 2
Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) contents of commercial
canned blueﬁn tuna vs a typical ﬁsh oil based pharmaceutical formulation (FOPF).*
Blueﬁn tuna (g/50 g) FOPF capsule 1000 mg (g  cps)
DHA 0.76 ± 0.55 0.62 ± 0.83
EPA 0.39 ± 0.40 0.38 ± 0.37
* Data are expressed as mean value (g/100 g fresh weight) ± SD (n = 5; P < 0.05).3. Results and discussion
The quali-quantitative lipid pattern of the commercial canned
ﬁsh samples analyzed is reported in Table 1. Blueﬁn tuna meat
revealed a higher percentage of n-3 PUFA in comparison with other
commercial ﬁsh species. Particularly, n-3 PUFA in blueﬁn tuna
accounted for 41.1% of total lipid respect to a range of 16.8–
39.8% of the other commercial samples, and DHA represented an
important constituent (26.9% vs a range of 14.2–34.2% of total
lipid) with the exception of yellowﬁn tuna (34.2%). As regards
the absolute values (g/100 g), blueﬁn tuna demonstrated the high-
est amount of n-3 PUFA and DHA, while salmon was the highest for
SAFA and n-6 PUFA (Table 1). A n-3/n-6 PUFA ratio of 1:6 is consid-
ered to be adequate for the nutritional needs for most healthy
adults, particularly when n-3 PUFA consist mainly of EPA and
DHA. Such ratio would exert an important inﬂuence on plasma lip-
ids and serve cardiac and endothelial functions to impact the pre-
vention and treatment of coronary heart diseases (CHD)
(Wijendran and Hayes, 2004; Makni et al., 2010). Today, this bal-
ance in the usual Western diet has been severely shifted, and the
amount of n-3 PUFA in the diet has decreased, while the amount
of n-6 PUFA has increased. A dietary intake of ﬁsh with high ratio
of n-3/n-6 PUFA would therefore be beneﬁcial (Wijendran and
Hayes, 2004). Blueﬁn tuna revealed not only an interesting n-3/n-
6 PUFA ratio (9.3 vs a range of 1.9–19.7) but, in particular, the high-
est amount of n-3 PUFA among the commercial samples analyzed
(Table 1).
Clinical trials and experimental studies suggest that EPA and
DHA have important antiatherogenic and antithrombotic proper-
ties deriving from a wide range of biological effects, including ben-
eﬁts on lipoprotein metabolism, blood pressure, endothelial
function and vascular reactivity, inﬂammation, platelet and ﬁbri-
nolytic function, cytokine production, coagulation and oxidative
stress (Mori and Woodman, 2006). The favorable effects of ﬁsh oils
were primarily attributed to EPA, despite the fact that some ﬁshes
provide substantial quantities of DHA. Even until recently, it was
unclear as to whether EPA or DHA were equally important in rela-
tion to cardiovascular protection. A limiting factor has been the
lack of sufﬁcient quantities of puriﬁed EPA or DHA, resulting in
the individual effects of EPA and DHA in humans being examined
in only a few controlled trials. These data now demonstrate that
DHA and EPA have both important haemodynamic and anti-ath-
erogenic properties, although they show independent effects on
cardiovascular risk factors in humans. Our experimental resultsrevealed that the EPA/DHA ratio in blueﬁn tuna sample was the
closest to the ideal one occurring in most of ﬁsh oil based pharma-
ceutical formulations (FOPF) among the commercial samples
tested. Our data regarding the EPA and DHA contents in the com-
mercial ﬁsh samples analyzed have been compared with the one
of a typical FOPF of which 1 capsule (1000 mg)/day is usually sug-
gested for the control of serum triglycerides in hyperlipidaemic
subjects or for the secondary prevention in patients with previous
myocardial infarction. Interestingly, our results revealed that the
EPA and DHA contents in a 50 g blueﬁn tuna portion are almost
equivalent to those of 1 capsule (1000 mg) of the same FOPF
(Table 2).
The correlation between intake of ﬁsh oil n-3 PUFA, mainly DHA
and EPA, and reduction of cardiovascular disease risk (Arino et al.,
2005), may indicate cardiac cell lines as a suitable model system
for testing the potential effects of ﬁsh oil extracts and their deriv-
atives on the cardiovascular physiology. A mixture of commercial
DHA and EPA standards was prepared simulating the same relative
proportions as in canned blueﬁn tuna lipid proﬁle, and has been
referred to as SBTDEM (Simulated Blueﬁn Tuna DHA and EPA Mix-
ture). The effect on cardiac derived H9C2 myocytes proliferation
exposed to increasing doses (0.01–1.8 lg) of SBTDEM and FOPF
lipid extracts was examined (Fig. 1). SBTDEM revealed a linear cor-
relation between incubation dose and cell proliferation, and the
maximum result was achieved with a 0.1 lg dose which made cell
proliferation increase by about 95%. The positive inﬂuence of n-3
PUFA cell membrane incorporation on the control of cell functions
relevant to cardiovascular diseases has already been reported.
Assimilation of n-3 PUFA into plasma membrane phospholipids
has major effects on cell signaling by altering membrane ﬂuidity,
lipid raft structure, and substrate availability for the synthesis of
bioactive oxidized fatty acids (Jump, 2002). DHA plays a key struc-
tural role in membrane architecture; this highly unsaturated fatty
acid alters membrane ﬂuidity, membrane cholesterol content, and
lipid raft organization (Wassall and Stillwell, 2009; Soni et al.,
2008). The impact on intracellular calcium handling is also partic-
ularly noteworthy. Stanley et al. (2012) recently identiﬁed the
mitochondrial permeability transition pore (MPTP) as a target for
n-3 PUFA regulation. MPTP is a large-diameter, high-conductance,
Fig. 1. Effect of a Simulated Blueﬁn Tuna DHA and EPA Mixture (SBTDEM) and a
typical ﬁsh oil based pharmaceutical formulation (FOPF) on H9C2 cardiomyocyte
proliferation. The 100% proliferation refers to untreated cells. Values are expressed
as means ± SD (n = 5; P < 0.05). abcdefghijkMean values with different superscript
letters are signiﬁcantly different by the Tukey–Kramer multiple comparison test.
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molecules up to 1.5 kDa. Mitochondrial accumulation of Ca2+
induces MPTP opening, whereas Ca2+ chelation closes the channel.
Opening of MPTP is linked to cell death and has been implicated in
ischemic injury and heart failure (Stanley et al., 2012; Duda et al.,
2007). The EPA-derived epoxide, 17(R),18(S)-epoxyeicosatetrae-
noic acid, has anti-arrhythmic effects; it rapidly and with high
potency (EC50  1–2 nM) protects neonatal cardiomyocytes against
Ca2+ overload (Falck et al., 2011). An additional mechanism at the
base of the potential cardiovascular protection is the nuclear effect
of n-3 PUFA on the inﬂammation process. NFjB is a major tran-
scription factor regulating expression of genes encoding proteins
involved in inﬂammation; some target genes include COX2, cyto-
kines (e.g., TNFa), and chemokines (e.g., MCP1) (Ben-Neriah and
Karin, 2011). n-3 PUFA, particularly, elevated cell membrane DHA
levels, have been reported to suppress the nuclear levels of NFjB
in several model systems and down-regulate acid sphingomyeli-
nase activity, leading to a decline in ceramide, an inﬂammatory
and pro-apoptotic lipid (Jump, 2004).
Similarly, data reported in Fig. 1 demonstrated that FOPF lipid
extract at a maximum sample dose of 0.1 lg was able to exert posi-
tive effects on cardiac cell proliferation. Nevertheless, exposure to
increasing concentrations resulted in a reversal of the observed
trend, and at a sample dose of 0.9 lg cytotoxic effects were
revealed. These results are consistent with what has been stated
in literature for fatty acid ethyl esters of which most of FOPF are
based. Fatty acid ethyl esters would be 50 times more resistant
to pancreatic lipase as compared to hydrolysis of triglycerides, so
that in part they would be bioavailable in their integral formTable 3
Effect of a simulated blueﬁn tuna DHA and EPA mixture (SBTDEM) and a typical ﬁsh oil b
lysate of H9C2 cardiomyocytes.*
Control Dox 1 lM Dox 1 lM
TBARS lM/lg protein 0.0043 ± 0.0005a 0.0068 ± 0.0008b 0.0021 ±
NO2 nmol/lg protein 0.0010 ± 0.0004a 0.0065 ± 0.0007b 0.0022 ±
MnSOD U/lg protein 0.0100 ± 0.001a 0.0180 ± 0.002b 0.0080 ±
a,b,c,d,eMean values in rows with different superscript letters are signiﬁcantly different b
Dox: doxorubicin; TBARS: Thiobarbituric Acid Reactive Substances; MnSOD: manganese
* Values are expressed as means ± SD (n = 5; P < 0.05 compared to the control).(Yang et al., 1990a,b). Once speciﬁc target tissues are reached, fatty
acid incorporation in the cell phospholipid bilayer would imply
trans-esteriﬁcation and consequent cell damages due to the
amount of ethanol released (Best and Laposata, 2003). Moreover,
it has been demonstrated that n-3 PUFA in the form of ethyl esters
are much less stable than those in the natural triglyceride form and
readily oxidize producing cytotoxic radical products (Yoshii et al.,
2002).
In order to ascertain the potential effects of canned blueﬁn tuna
n-3 PUFA on the doxorubicin-induced oxidative stress in cardiac
cells, H9C2 cardiomyocytes were exposed to 1 lM doxorubicin
and a combination of doxorubicin and different doses of SBTDEM
and FOPF lipid extracts for 72 h (Table 3). Maximum aliquot of
0.1 lg SBTDEM provided an appreciable radical-scavenging activ-
ity as indicated by the decrease in the free-radical levels (especially
ROS species, about 31%) and the unchanged antioxidant defense
system activity (Table 3). Similarly, the association of doxorubicin
with maximum FOPF lipid extract dose of 0.1 lg revealed positive
effects on induced cardiac cell oxidative stress. These results would
conﬁrm that dietary n-3 PUFA supplementation is associated with
a reduction in the susceptibility of myocytes to ROS-induced injury
and this may be related to membrane incorporation of n-3 PUFA,
increased antioxidant defense systems, changes in cardiomyocyte
membrane ﬂuidity, and the ability to prevent rises in cellular
Ca2+ in response to ROS (Jahangiri et al., 2006). On the contrary,
the co-administration of higher FOPF lipid extract doses led to
the enhancement of cardiac cell oxidative stress, probably due to
the sample pro-oxidant effects (ethanol released and secondary
unstable oxidized derivatives), as indicated mainly by the increase
in RNS and antioxidant enzyme levels (Table 3).
To conﬁrm such hypothesis, the inﬂuence of 1 lM doxorubicin
and a combination of doxorubicin with different SBTDEM and FOPF
lipid extract doses on caspase-3 activity in cardiomyocytes was
assayed (Fig. 2). Among the many known regulators and effectors
of apoptosis, caspases are a family of cytoplasmic proteases that
plays an important role in the execution phase of apoptosis. Two
groups of caspases can be identiﬁed: upstream initiator caspases,
that cleave and activate other caspases, and downstream effector
caspases, including caspase-3, caspase-6, and caspase-7, that
cleave a variety of cellular substrates or inactivating enzymes. Cas-
pase-3 is a central executioner in apoptosis (Thornberry and
Lazebnik, 1998). Cells were incubated with doxorubicin and a com-
bination of doxorubicin and different doses of SBTDEM and FOPF
lipid extracts in medium for 8 h and then lysed to measure cas-
pase-3 activity using a ﬂuorogenic assay. Our results showed that
doxorubicin signiﬁcantly up-regulated caspase-3 activity while
its combination with maximum sample aliquot of 0.1 lg SBTDEM
seemed to effectively depress (by about 50%) the activity of this
apoptotic factor (Fig. 2). An almost comparable result was obtained
with 0.1 lg of FOPF lipid extract. Interestingly, an increase in FOPF
lipid extract dose exposure to cardiomyocytes seemed to be less
effective in reducing caspase-3 activity. Collectively, these data
suggested that higher doses of FOPF lipid sample caused cell death
via the caspase-3-mediated apoptotic pathway.ased pharmaceutical formulation (FOPF) on doxorubicin-induced oxidative stress in
+ 0.1 lg SBTDEM Dox 1 lM + 0.1 lg FOPF Dox 1 lM + 0.9 lg FOPF
0.0003c 0.0034 ± 0.0003d 0.0088 ± 0.0007e
0.0003c 0.0032 ± 0.0004d 0.0240 ± 0.001e
0.0006c 0.0110 ± 0.001a 0.0350 ± 0.001d
y the Tukey–Kramer multiple comparison test.
superoxide dismutase; Control: untreated cell lines.
Fig. 2. Effect of doxorubicin (Dox) in association with a Simulated Blueﬁn Tuna
DHA and EPA Mixture (SBTDEM) and a typical ﬁsh oil based pharmaceutical
formulation (FOPF) on caspase-3 activity in lysate of H9C2 cardiomyocytes. Values
are expressed as means ± SD (n = 5; P < 0.05). abcdeMean values with different
superscript letters are signiﬁcantly different by the Tukey–Kramer multiple
comparison test. Control: untreated cell lines.
G.C. Tenore et al. / Food and Chemical Toxicology 71 (2014) 231–235 2354. Conclusion
Canned blueﬁn tuna showed the most interesting lipid proﬁle,
as regards their potential health beneﬁts, among the different Ital-
ian commercial canned ﬁsh species analyzed. Tests on H9C2
cardiomyocytes revealed that blueﬁn tuna n-3 PUFA may be
responsible for a signiﬁcant cell protection against both physiolog-
ical and doxorubicin-induced oxidative stress. Analogous tests per-
formed by incubating cardiac cells with FOPF lipid extract showed
cytotoxicity at high doses conﬁrming that fatty acid ethyl esters, of
which most of FOPF are based, would release ethanol and would be
less stable to oxidative processes than triglycerides. Our results
highlighted that EPA and DHA contents in a 50 g canned blueﬁn
tuna portion would be almost equivalent to and potentially safer
than those of 1 FOPF capsule (1000 mg)/day usually suggested
for the control of serum triglycerides in hyperlipidaemic subjects
or for the secondary prevention in patients with previous myocar-
dial infarction. Thus, canned blueﬁn tuna could be indicated as a
functional food potentially useful for the prevention and care of
cardiovascular disorders. Undoubtedly, further in vivo and clinical
studies are needed to support these results.
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